Wellington Management Group LLP Ventyx Biosciences, Inc. Transaction History

Wellington Management Group LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$29.8 - $40.3 $198,319 - $268,196	-6,655 Reduced 0.49%	1,342,977 $46.6 Million
Q2 2023 Aug 14, 2023	BUY	$28.53 - $39.55 $13.7 Million - $18.9 Million	479,127 Added 55.04%	1,349,632 $44.3 Million
Q1 2023 May 12, 2023	BUY	$29.51 - $46.65 $7.68 Million - $12.1 Million	260,232 Added 42.64%	870,505 $29.2 Million
Q4 2022 Feb 13, 2023	SELL	$24.16 - $36.38 $4.52 Million - $6.81 Million	-187,172 Reduced 23.47%	610,273 $20 Million
Q3 2022 Nov 14, 2022	SELL	$12.64 - $38.7 $1.27 Million - $3.88 Million	-100,176 Reduced 11.16%	797,445 $27.8 Million
Q2 2022 Aug 15, 2022	SELL	$11.95 - $18.75 $7.23 Million - $11.4 Million	-605,350 Reduced 40.28%	897,621 $11 Million
Q1 2022 May 16, 2022	SELL	$10.0 - $19.98 $3.26 Million - $6.5 Million	-325,557 Reduced 17.8%	1,502,971 $20.3 Million
Q4 2021 Feb 11, 2022	BUY	$14.2 - $23.07 $26 Million - $42.2 Million	1,828,528 New	1,828,528 $35.7 Million

125

52.9M

35.3K

83K

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $128M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

Stay updated on Wellington Management Group LLP with notifications on news.